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Abstract
Background: In some countries that have introduced oral rotavirus vaccines, a small but
elevated risk of intussusception—a rare bowel disorder—has been reported. Updated
estimates on the global epidemiology of intussusception are needed to help predict the
potential number of intussusception cases that could be caused by the vaccine in differ-
ent settings.
Methods: We estimated incidence rates, age distributions and case-fatality ratios (CFRs)
for intussusception hospital admissions among children aged <5 years, before the intro-
duction of rotavirus vaccines. We included all articles identified in a systematic review
between January 2002 and January 2018, and contacted authors for more granular
unpublished data on age distributions.
Results: We identified 128 articles containing 227 country datasets (61 age distributions,
71 incidence rates and 95 CFRs). The median age of intussusception ranged from
29 weeks in Africa (83% of cases in the first year of life) to 70 weeks in the Western Pacific
region (35% of cases in the first year of life). The median (range) annual incidence of in-
tussusception hospital admissions per 100 000 aged <1 year ranged from 34 (13–56) in
Africa to 90 (9–380) in the Western Pacific region. We found extreme differences between
the CFRs in Africa (1 death in every 10 hospital admissions) and the rest of the world
(fewer than 1 death in every 100–2000 hospital admissions).
VC The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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Conclusion: Intussusception epidemiology varies by country and region. Understanding
and recognizing these differences will be important when assessing the potential
number of intussusception cases associated with rotavirus vaccines.
Key words: Intussusception, epidemiology, age, incidence, mortality
Introduction
Intussusception is the main cause of bowel obstruction in
children aged <5 years. It occurs when a segment of the in-
testine telescopes or folds back on itself.1 This blocks the
passage of food and liquid through the intestine and
restricts the supply of blood to the affected area. Some
cases of intussusception will spontaneously resolve without
treatment, but delayed diagnosis can lead to perforation
and infection in the lining of the abdominal cavity (perito-
nitis). Peritonitis can cause severe abdominal pain, fever,
shock and death.2 In high-income countries, most children
are diagnosed quickly with ultrasound or radiograph and
the bowel will return to normal after injecting a liquid or
gas into the rectum (enema). In more severe cases, surgery
is usually very successful. However, in parts of Africa and
elsewhere, many children will die before reaching health-
care; for those who do reach healthcare, surgery is often
the primary method of diagnosis and treatment, leading to
death in 10% of cases.3
The cause of intussusception is usually unclear, but
infections that cause swelling in the bowel wall may be
associated.4 In some countries that have introduced oral
rotavirus vaccines, a small but elevated risk of intussuscep-
tion has been reported in the first few weeks after adminis-
tration of the first and second doses. To limit the scale of
potential vaccine-related intussusception cases, the vaccine
manufacturers have recommended administration of the
first dose before 15 weeks of age (and the final dose be-
fore 32 weeks of age) when the background rate of intus-
susception is relatively low.5
Published intussusception incidence rates, age distribu-
tions and case-fatality ratios (CFRs) have been reviewed
and published by the World Health Organization (WHO)
(1960–2002)2 and Jiang et al. (2002–12)3 but there are a
number of reasons why this evidence should now be
updated. First, many new studies have been published since
2012. Second, age distributions and incidence rates were
previously restricted to children aged <1 year despite many
cases being observed between the ages of 1.0 and 5.0 years
in some settings.6–8 Third, CFRs were estimated for a vari-
ety of age groups rather than a standard (e.g. <5 years),
making it difficult to compare countries and estimate ratios
in countries with no data. Fourth, published intussuscep-
tion age distributions are rarely published by week of age.
Obtaining data from authors/investigators at this level of
age granularity will provide inputs that are critical for
modelling the number of excess intussusception cases that
could be associated with different rotavirus vaccination
schedules in different settings. This calculation involves
combining estimates of the background number of intus-
susception cases in each week of age with data on the cov-
erage of each dose in each week of age9 and the relative
risk of intussusception in the first, second and third weeks
after each dose is administered.10
In this paper, we provide an updated global review of
the incidence, age distribution and case fatality of intussus-
ception hospital admissions among children aged <5 years
of age, before the introduction of rotavirus vaccination.
Methods
Search strategy
We sought information from published research articles
on intussusception incidence rates, age distributions and
Key Messages
• Intussusception incidence varies substantially by country and region, highlighting the need to assess the benefits and
risks of rotavirus vaccines at the national, rather than global, level.
• Administering the first dose of rotavirus vaccination at birth, rather than at 6 weeks, could avoid nearly all vaccine-
related cases of intussusception.
• We found extreme differences between case-fatality ratios in Africa (1 death in every 10 hospital admissions) and the
rest of the world (fewer than 1 death in every 100–2000 hospital admissions), highlighting the urgent need for strate-
gies to reduce the time between onset of symptoms and presentation at hospital.
2 International Journal of Epidemiology, 2019, Vol. 0, No. 0
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/advance-article-abstract/doi/10.1093/ije/dyz028/5382176 by London School of H
ygiene & Tropical M
edicine user on 29 M
arch 2019
CFRs in children aged <5 years, before the introduction of
rotavirus vaccination. We included all studies published
between January 2002 and June 2012 that were identified
in a previous review by Jiang et al.3 We then added all rele-
vant studies published between June 2012 and January
2018, identified from a new global systematic literature re-
view. This review used search terms that were consistent
with the review by Jiang et al., i.e. ‘intussusception’ or ‘in-
testinal invagination’. It was conducted in accordance with
PRISMA guidelines. We searched PubMed, EMBASE,
MEDLINE and Cochrane Library. We restricted the search
to articles published in English, French, Spanish and
Polish. To increase the relevance of our analysis, we ex-
cluded all studies published before January 2002. We
therefore excluded all studies from an earlier review by
WHO (1960–2002).2 All titles and abstracts identified by
the systematic review were screened for inclusion by two
reviewers (M.H.A. and L.K.S) using Distiller software.
Any disagreements were resolved by a third reviewer
(A.D.C.). Articles were excluded if: (i) it was not possible
to extract data for the years prior to rotavirus-vaccine in-
troduction; (ii) the data period ended prior to the year
2000; (iii) cases were not coded as ICD9-560, ICD10-
K56.1, Brighton Collaboration Level 1 (BCL1) or defined
clinically as intussusception; (iv) there were fewer than 35
cases (for age-distribution fitting); (v) more recent data
were published elsewhere for the same population/location
(for incidence rates); (vi) they described animal studies;
(vii) they described individual case reports; (viii) they fo-
cused on a specific subgroup of cases, e.g. only patients
with chronic or recurrent intussusception; (ix) they were
conducted in special populations, e.g. HIV-positive; or (x)
the study had a high risk of bias. All remaining studies
were assigned very low, low or medium risk of bias (see
Supplementary Appendix Table A1, available as
Supplementary data at IJE online). If information from
multiple countries was published as a single data point, it
was included if all countries were from the same WHO re-
gion and it was clear that none of the country-level data
were reported elsewhere.
Data extraction
We compiled a database containing information on intus-
susception incidence rates, age distributions and CFRs in
children aged <5 years. For all studies, we extracted the
country, subnational location, study design, case defini-
tion, period of data collection and age range. To obtain
more granular age distributions, we emailed an invitation
letter to all authors who were listed in the Jiang et al. re-
view (2002–12)3 and all authors identified in the new sys-
tematic review (2012–18). We invited each author to share
a spreadsheet table with counts of intussusception hospital
admissions by week of age up to 5.0 years. If the authors
did not respond, then we extracted the age distributions
published in the research article. We also extracted the
published incidence rate and the number of intussusception
cases and deaths.
A country dataset was defined as any dataset with hos-
pitalized patients before the introduction of rotavirus vac-
cine, taken from a single study in a single country and
reporting on a single outcome, e.g. age distribution, inci-
dence rate and CFR. If a study included multiple years and
multiple sites, then all pre-vaccination years and subna-
tional sites were aggregated and included in the same coun-
try dataset. The main outcome/presentation was hospital
admissions, but we also included emergency room visits if
admissions were not reported in the same study.
Age distribution of intussusception hospital
admissions <5 years
Age distributions were fitted to all studies that had at least
three age bands below the age of 1.0 year to ensure there
was enough information to inform the shape of the age dis-
tribution. Age distributions that did not capture the entire
age range <5 years (e.g. <1 year, <2 years) were adjusted to
ensure that each country dataset had a realistic right-hand
tail prior to fitting. To do this, we calculated the median
cumulative proportion of intussusception cases that were
reported to have occurred by ages 1, 2, 3, 4 and 5 years in
each WHO region, using a subset of country datasets that
had a full set of counts in each single year of age up to
5.0 years. The median proportions in each WHO region
were then used to estimate the expected number of intussus-
ception cases in each missing single year of age <5 years.
We fitted a range of parametric age distributions
<5 years (Gamma, Weibull, Lognormal, Log Logistic, Burr)
to each country dataset using Non-linear Least Squares
(NLS) and Maximum Likelihood Estimation (MLE). Each
distribution was compared using the Root Mean Squared
Error (RMSE), Mean Absolute Error (MAE), goodness-of-
fit statistics (Kolmogorov-Smirnov, Cramer-von Mises,
Anderson-Darling) and goodness-of-fit criteria (Akaike’s
Information Criterion, Bayesian Information Criterion).
We estimated the median age, interquartile age range and
cumulative proportion of intussusception cases estimated to
have occurred by standard ages between birth and age
5.0 years. All analyses were conducted using R (R version
3.4.1, R Foundation for Statistical Computing, Vienna,
Austria) and the R packages MASS, nloptr, fitdistrplus,
actuar and mutil.
Results were stratified by the following WHO regions:
the Americas (AMR); Africa (AFR); Eastern Mediterranean
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(EMR); Europe (EUR); Southeast Asia (SEA); and Western
Pacific (WPR).11
Incidence of intussusception hospital admissions
<5 years
For country datasets that did not capture the entire age
range <5 years (e.g. <1 year, <2 years) we calculated an
adjusted incidence rate per 100 000 per year <5 years.
First, we estimated the expected number of cases in each
missing single year of age <5 years using the median cumu-
lative proportion of intussusception cases by ages 1, 2, 3, 4
and 5 years in each WHO region. These median propor-
tions were based on the entire set of fitted parametric age
distributions <5 years, so included more studies than those
used to adjust the right-hand tails of age distributions prior
to fitting (see above). Second, we inflated the denominator
based on the ratio between the size of the population in the
reported age group and the under-five age group. Ratios
were determined using UNPOP population data for ages 0,
1, 2, 3 and 4 years in the period 2010–15.12 Results were
stratified by WHO region.
In-hospital intussusception CFRs <5 years
We used three alternative approaches to estimate CFRs for
each country dataset and each WHO region. First, we cal-
culated age-unadjusted CFRs by dividing reported deaths
by reported cases in each country and WHO region.
Second, we calculated age-unadjusted CFRs and 95% con-
fidence intervals (CIs) for each country and WHO region
using meta-analysis. For meta-analysis, we used the meta-
prop_one and metareg commands in Stata version 15.1
(StataCorp. 2017. Stata Statistical Software: Release 15.
College Station, TX: StataCorp LLC). With metapro-
p_one, we chose the logit option, so that binomial distribu-
tions were used to model within-study variability. Logistic
models with random intercepts were fitted and the vari-
ability of the random intercepts indicated heterogeneity.
We also ran a separate meta-analysis with results pooled
by the national under-five mortality quintile. Quintiles
were based on the 2010–15 under-five mortality rates pub-
lished by the UNPOP (2017 Revision).12 Third, we calcu-
lated age-adjusted CFRs by converting CFRs that did not
extend the full 5-year age range (e.g. <1 year, <2 years)
into a CFR aged <5 years. To do this, we first calculated
the expected number of intussusception cases in the miss-
ing age range (e.g. 12–59 months) using the median cumu-
lative proportion of cases expected to occur by each age in
each WHO region. These estimates were based on the full
set of fitted parametric age distributions <5 years in each
WHO region. To estimate CFRs in the missing age range,
the ratio of difference between the CFR in the known and
missing age range was assumed to be the same as the ratio
of difference between the probability of dying from any
cause in the known and missing age ranges during a single
year of life. These probabilities were derived from country-
specific life tables for the period 2010–15.12
Results
Search results
After exclusions, we identified 128 articles (Figure 1). We
included 62 articles from the Jiang et al. review (2002–12)
and 66 articles from the new search (2012–18). There were
61 country datasets with age distributions, 71 with inci-
dence rates and 95 with CFRs (Supplementary Appendix
Table A1, available as Supplementary data at IJE online).
We obtained additional age granularity from authors in
around half (28/61) of the country datasets with age distri-
butions. We included post-vaccination age distribution and
CFR data for one study in Africa13 because it included
high-quality prospective data for several African countries
and found no elevated risk of intussusception. We also in-
cluded data from China and Vietnam despite uncertainties
about the level of vaccine use in the private market. We in-
cluded data from four studies that were published after the
end date of the systematic review.13–16
Age distribution of intussusception hospital
admissions <5 years
Prior to fitting, we used a subset of 31 datasets with com-
plete counts in each single year of life between birth and
age 5.0 years (Supplementary Appendix Table A2, avail-
able as Supplementary data at IJE online) to estimate real-
istic right-hand tails in the datasets with incomplete age
distributions <5 years. Using MLE, in most of the 61 coun-
try datasets, the Burr distribution had the most favourable
goodness-of-fit statistics and goodness-of-fit criteria com-
pared with the Weibull, Lognormal, Gamma and Log
Logistic distributions. However, the fits based on NLS had
a lower overall RMSE and a much better visual fit to the
data than MLE, particularly around the peak of the age
distribution (Figure 2). The Burr distribution had more
favourable RMSE and MAE statistics than the Log
Logistic distribution in over 80% of the country datasets
and a better visual fit to distributions with long tails. Our
preference was to use a standard approach to fitting,
summarizing and extrapolating curves to countries without
data so we fitted the Burr distribution to all 61 data-
sets17,18 (Supplementary Appendix Table A3, available as
Supplementary data at IJE online).
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Figure 1. Flow diagram to show search for country datasets.
Figure 2. Comparison of fitted age distributions for intussusception hospital admissions among children aged <5 years for selected country datasets.
(A) England (2002–12); (B) USA (1994–2004); (C) Hong Kong (1997–2011); (D) Taiwan (1998–2013).
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In the African, Eastern Mediterranean and Southeast
Asian regions, 80% of intussusception hospital admis-
sions were in the first year of life, compared with 63% in
the Americas, 54% in Europe and 35% in the Western
Pacific region. The median proportion of cases occurring
by 15 weeks of age ranged from 2.4% in the Western
Pacific region to 6.8% in the Eastern Mediterranean region
(Table 1). There was substantial within-region variation in
the European and the Western Pacific regions
(Supplementary Appendix Table A4, available as
Supplementary data at IJE online).
Median (IQR) ages of intussusception hospital admis-
sions were: 29 (22–43) weeks in Africa, 30 (22–42) weeks
in the Eastern Mediterranean, 33 (24–47) weeks in
Southeast Asia, 41 (27–69) weeks in the Americas, 47 (29–
89) weeks in Europe and 70 (42–126) weeks in the
Western Pacific region (Figure 3).
Incidence of intussusception hospital admissions
<5 years
The median (range) annual incidence rate of intussuscep-
tion hospital admissions was 8 (3–14) per 100 000 aged
<5 years in Africa, 11 (1–34) in the Americas, 19 (13–23)
in the Eastern Mediterranean region, 14 (4–49) in Europe,
19 (4–61) in Southeast Asia and 52 (5–196) in the Western
Pacific region (Figure 4 and Table 1). Incidence rates in the
Western Pacific region ranged from 5 in Malaysia to
200 in Nha Trang, Vietnam. Incidence rates above 70
per 100 000 per year <5 years were found in Japan, South
Korea and Vietnam (Supplementary Appendix Table A5,
available as Supplementary data at IJE online). Globally,
we found no correlation (R2< 0.1%) between the adjusted
incidence rates <5 years and the under-five mortality rate
for the period 2010–15. Median incidence rates among
children aged <1 year were above 75 per 100 000 per year
in Southeast Asia and in the Eastern Mediterranean and
Western Pacific regions (Table 1 and Figure 4).
In-hospital intussusception CFRs <5 years
Pooled CFRs in each WHO region varied according to the
method used (Table 1). The CFR (95% CI for each region)
based on age-unadjusted meta-analysis was 11.5% (7.24–
17.78%) in Africa, 0.41% (0.11–1.54%) in the Americas,
0.46% (0.02–8.74%) in the Eastern Mediterranean region,
0.20% (0.05–0.89%) in Europe, 0.27% (0.03–2.48%) in
Southeast Asia and 0.05% (0.02–0.12%) in the Western
Pacific region, but there was variation within each region
(Table 1, Supplementary Appendix Table A6, available as
Supplementary data at IJE online). We chose to stratify by
WHO region rather than under-five mortality quintile.
Both had similar explanatory power in meta-regression
(p< 0.005) but WHO region was consistent with the strat-
ification used for age distributions and incidence rates, and
had more favourable between-group heterogeneity
(p¼ 0.001 vs p¼ 0.003). The strongest predictor of CFRs
was whether a country was based in the region of Africa or
not. Stratifying by study age group gave no evidence of het-
erogeneity (p¼0.7732) so CFRs were not adjusted for age
in meta-analysis.
Discussion
This analysis provides an important update to the existing
global evidence on intussusception incidence rates, age dis-
tributions and CFRs prior to rotavirus-vaccine introduc-
tion. More than half of the research articles (67/129)
included in our analysis were published after the previous
review by Jiang et al.3 In addition, we have provided inci-
dence rates and CFRs that are both unadjusted and ad-
justed to a standard age group (<5 years), allowing the
totality of evidence to be included and compared across
countries. We have also benefited from the generosity of
many study investigators, who were able to share a more
precise breakdown of their age data. We fitted standard
parametric curves to all datasets using statistically robust
methods that will allow estimates of intussusception cases
in each week of age <5 years.
Our analysis found that the median annual incidence of
intussusception ranges from 34 (African region) to 90
(Western Pacific region) per 100 000 children aged
<1 year. The previous review by Jiang et al. estimated a
global incidence of 74 in the same age range.3 Several
Western Pacific countries reported very high incidence
rates. The reason for this is unclear. A case–control study
in Vietnam and Australia found no association between in-
tussusception and diet or living conditions but did find a
strong association with adenovirus, suggesting this may
play a role in the aetiology of intussusception.19 High inci-
dence may also be associated with a high rate of recurrent
cases. However, recurrent cases represented <15% of total
intussusception hospital admissions in each of the 32 stud-
ies where this proportion was reported. In one study from
the Western Pacific region, we were able to exclude the re-
current cases and the median age was still high
(67 weeks).16 There were very few incidence-rate data
points from the African region (two data points) and
Eastern Mediterranean region (three data points).
Relatively low incidence rates from these regions may sim-
ply reflect the fact that many children did not reach hospi-
tal. For all datasets, we accepted the definition of
intussusception provided by the authors. However, differ-
ent definitions and coding systems could have led to
6 International Journal of Epidemiology, 2019, Vol. 0, No. 0
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Table 1. Incidence rates, age distributions and CFRs among intussusception hospital admissions aged <5 years in different
WHO regions before the introduction of rotavirus vaccination
Africa Americas Eastern
Mediterranean
Europe Southeast
Asia
Western
Pacific
Annual incidence (range) per 100 000 per year
Number of country datasets 2 20 3 19 7 20
<1 year 34 (13–56) 36 (4–105) 78 (51–95) 41 (12–138) 77 (18–253) 90 (9–380)
<5 years 8 (3–14) 11 (1–34) 19 (13–23) 14 (4–49) 19 (4–61) 52 (5–196)
Median age (inter-quartile range) of admission
Number of country datasets 14 7 4 13 7 16
Age in weeks 29 (22–43) 41 (27–69) 30 (22–42) 47 (29–89) 33 (24–47) 70 (42–126)
Median parameters of the Burr distribution
Shape 1 (c) 4.80 3.62 4.08 2.81 4.17 2.65
Shape 2 (a) 0.44 0.39 0.65 0.44 0.55 0.51
Scale (h) 22.20 26.15 25.46 29.33 26.39 46.83
Median cumulative % of admissions by agea
6 weeks 0.1% 0.2% 0.2% 0.5% 0.1% 0.2%
10 weeks 0.9% 1.2% 1.4% 2.0% 1.0% 0.8%
14 weeks 4.4% 3.8% 5.3% 5.0% 3.7% 2.0%
15 weeks 6.0% 4.8% 6.8% 6.0% 4.9% 2.4%
1 month 0.0% 0.1% 0.0% 0.2% 0.0% 0.1%
2 months 0.5% 0.7% 0.8% 1.4% 0.5% 0.6%
3 months 3.2% 3.0% 4.0% 4.1% 2.8% 1.7%
4 months 11.0% 7.7% 11.5% 8.6% 8.5% 3.5%
5 months 24.3% 14.8% 23.7% 14.4% 18.3% 6.1%
6 months 39.4% 23.5% 37.9% 21.0% 30.7% 9.3%
7 months 52.5% 32.3% 51.4% 27.7% 43.3% 13.1%
8 months 62.7% 40.5% 62.4% 34.2% 54.4% 17.4%
9 months 70.2% 47.7% 70.8% 40.1% 63.3% 21.8%
10 months 75.9% 53.9% 77.1% 45.5% 70.2% 26.3%
11 months 80.1% 59.0% 81.8% 50.2% 75.6% 30.8%
12 months 83.4% 63.4% 85.4% 54.4% 79.8% 35.1%
18 months 92.9% 78.9% 94.8% 70.8% 91.9% 55.6%
24 months 96.1% 85.9% 97.6% 79.2% 95.8% 68.1%
36 months 98.3% 92.0% 99.2% 87.3% 98.4% 80.9%
48 months 99.1% 94.7% 99.6% 91.0% 99.2% 87.0%
60 months 99.4% 96.1% 99.8% 93.2% 99.5% 90.3%
Case-fatality ratio
Number of country datasets 27 13 4 17 16 18
Pooled number of deaths 407 117 3 18 8 6
Pooled number of cases 3, 739 47, 616 368 10, 365 2, 467 11, 606
CFR (unadjusted) 10.89% 0.25% 0.82% 0.17% 0.32% 0.05%
CFR (adjusted to age <5 years) 10.08% 0.17% 0.81% 0.17% 0.32% 0.03%
CFR (age-unadjusted) meta-analysis 11.50% 0.41% 0.46% 0.20% 0.27% 0.05%
CFR (age-unadjusted) meta-analysis,
95% CI
(7.24–17.78%) (0.11–1.54%) (0.02–8.74%) (0.05–0.89%) (0.03–2.48%) (0.02–0.12%)
aThe best-fitting parameters for each WHO region were calculated by refitting Burr distributions to the pooled proportion of intussusception admissions in
each week of age <5 years. Cumulative proportions below 100% by age 60 months indicate that some cases are estimated to occur after this age. The Burr distri-
bution (Burr type XII) has shape 1 (c), shape 2 (a) and scale (h), all of which must be positive values (note: the Burr distribution becomes the Log Logistic distribu-
tion when the shape 2 parameter equals 1.0). The cumulative distribution function (cdf) of the Burr distribution is:
f xð Þ ¼ 1 1þ xh
 ch ia:
The three parameters (c, a, h) can also be used to derive the probability density function, median, mode, mean and variance. These equations are described in
detail elsewhere.18
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important differences in results. One study in Bangladesh
found a very large range of possible incidence rates (0–97
per 100 000 per year, <2 years) depending on whether the
study was retrospective or prospective, and whether cases
were probable or confirmed.20 Around one-third (25/71)
of the country datasets with incidence rates were based on
studies with a prospective design and most (63/71) used
specific ICD codes or BCL case definitions. We excluded
incidence rates if a more recent data point was reported in
the same population/location but there is some evidence
that incidence rates may be decreasing over time. In
England, estimates of the annual incidence of intussuscep-
tion hospital admissions <1 year were 66 for the period
1993–95,21 30 for the period 2002–12 (unpublished from 10)
and 24 for the period 2008–09.22 In California, the rate de-
clined from in 51 in 1985–97 to 37 in 2000–05.23
Countries with higher incidence rates tended to have a
higher median age. This effect was largely driven by coun-
tries in the Western Pacific region where high incidence
rates and high median ages were commonly reported. Our
Figure 3 Age distribution of intussusception hospital admissions among children aged <5 years by WHO region. (A) Africa; (B) Americas; (C) Eastern
Mediterranean; (D) Europe; (E) Southeast Asia; (F) Western Pacific.
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analysis of age distributions found median ages ranging
from 29 weeks in Africa (83% of cases in the first year of
life) to 70 weeks in the Western Pacific region (35% of
cases in the first year of life). However, regional medians
may mask important within-region variation and, in some
regions, the data are from a relatively limited subset of
countries that may not be representative of all countries
within the region. For example, the country datasets in
Switzerland and Germany had a much higher median age
of intussusception than the median for the European region
and many of the studies from Africa were from
Anglophone rather than Francophone countries. We did
not fit granular age distributions to datasets with fewer
than 35 cases to ensure the fits were reliable, but this
meant excluding some studies from e.g. Malawi and
Rwanda. In a small number of studies with very high me-
dian ages, there was some evidence of a second peak
shortly after the first.6,24–27 In these studies, our best-
fitting age distributions under-estimated cases among older
children (Figure 2) but the fits were generally very good in
the age range of importance to measuring vaccine-associated
intussusception events. The observed decreases in incidence
<1 year in England and the USA partly reflect a shift in
intussusception cases to older age groups over time.
National Inpatient Survey (NIS) data representing 20% of
hospitals in the USA have shown that the proportion of
under-five intussusception admissions aged <1 year has de-
clined from 62% in 1994 to 50% in 2004 and continues to
decline in the post-vaccine era (unpublished from 28).
We found extreme differences between the CFRs in
Africa (1 death in every 10 hospital admissions) and the
rest of the world (fewer than 1 death in every 100–2000
hospital admissions). In Africa, many children arrive late
to hospital in advanced stages of illness. Compared with
other parts of the world, a very high proportion of cases
are diagnosed and treated with surgery.29,30 Strategies are
urgently needed to reduce the time between onset of symp-
toms and presentation at hospital. Removing barriers to
timely access in Africa would dramatically reduce the risk
of complications and other contraindications that prohibit
the use of lower-risk treatment options, such as enemas.
Investment is also needed to ensure hospitals have the ap-
propriate imaging equipment (ultrasound, radiograph) and
staff required to implement lower-risk treatment.18 We did
not formally evaluate the proportion of cases receiving dif-
ferent types of diagnostics and treatment in different set-
tings. This would be a worthwhile follow-up analysis and
would inform estimates of the costs of intussusception
treatment in different settings.
Our analysis excludes children without access to
hospital. Most children with intussusception will die if
left untreated, but an uncertain proportion will spont-
aneously resolve without treatment.31–35 Better estimates
of access to hospital, and spontaneous recovery without
treatment, would be needed to generate realistic estimates
of the CFR among all cases of intussusception.36 These
adjustments could be influential in Africa, leading to
higher overall CFRs than reported in our analysis of hos-
pital admissions.
In the context of rotavirus vaccines, a recent study in
Africa encouragingly found no intussusception risk associ-
ated with a live oral rotavirus vaccine,13 but an elevated
risk has been found with the same vaccine, and other oral
rotavirus vaccines, in other parts of the world. The authors
provide several reasons why the risk may have been lower
in the African study including less frequent shedding of the
vaccine strain in lower-income settings, co-administration
with oral polio vaccination and administering the vaccine
at a younger age (6 and 10 weeks).37 Our analysis provides
inputs that are critical to assess the number of excess intus-
susception cases that could be associated with different ro-
tavirus vaccination schedules in different settings. It is
important to evaluate this at the national level given the
substantial country-level variation observed in age distri-
butions, incidence rates and CFRs, as well as vaccine
Figure 4. Incidence of intussusception hospital admissions by WHO re-
gion. (A) <1 year; (B) <5 years.
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schedules, coverage and timeliness.5,9 Avoiding the peak
age of intussusception is important for the design of rotavi-
rus vaccination schedules because the absolute risk is rela-
tive to the background incidence. Our analysis
encouragingly found that less than 5% of hospital admis-
sions occurred before age 15 weeks (median of all 71 data-
sets) when the first dose is typically administered. If the
first dose of rotavirus vaccination could be administered at
birth,38 this would avoid nearly all of the background inci-
dence. Large-scale post-licensure studies are needed to as-
sess whether this strategy can substantially lower the risk
of intussusception, without reducing the benefits of rotavi-
rus vaccination. We excluded case counts recorded in the
first week of life. Several datasets reported a suspiciously
high number in this age group, which may be related to
errors in the recording of the date of birth/admission or
errors in the diagnosis. For example, necrotizing enteroco-
litis and other neonatal congenital problems may be mis-
diagnosed as intussusception.39
Conclusion
The incidence, age distribution and case fatality of intus-
susception hospital admissions vary by region.
Understanding and recognizing these differences will be
important when assessing the number of intussusception
cases that could be associated with different rotavirus vac-
cination schedules in different settings.
Supplementary data
Supplementary data are available at IJE online.
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